2551 Drew Street, Suite 206 | Clearwater, FL 33765 Monday - Thursday 9AM - 4PM, Friday 9AM - 12PM 727-998-4400
Research

There are over 200,000 peer reviewed scientific publications on www.pubmed.gov regarding Human Cell Tissue Transplantation and Stem Cell Therapy.

Thousands of these studies show positive outcomes. We invite all potential patients to research and educate themselves on the potential benefits of Regenerative medicine including the use of human cell tissue.

References
  1. Gonzalez R, Woynarowski D, Geffner N. (2015). Stem Cells Targeting Inflammation as Potential Anti-aging Strategies and Therapies. Cell & Tissue Transplantation & Therapy 7 1–8.
  2. Guillot P.V., O’Donoghue K., Kurata H., Fisk N.M. (2006). Fetal stem cells: Betwixt and between, Semin. Reprod. Med. 24 (5) 340–347.
  3. Gislane L, et al. (2015). Bone Marrow Mesenchymal Stromal Cells Isolated From Multiple Sclerosis Patients Have Distinct Gene Expression Profile and Decreased Suppressive Function Compared With Healthy Counterparts. Cell Transplantation, Vol. 24, pp. 151–165.
  4. Prockop D. (2007). “Stemness” does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs). Clin Pharmacol Ther. 82(3):241-3.
  5. Caplan AI. (2007). Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol. 213(2):341-7.
  6. Le Blanc K, Ringden O. (2007). Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med.262(5):509-525.
  7. Aggarwal S, Pittenger MF. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 105 (4):1815-1822.
  8. Amorin B, et al. (2014). Mesenchymal stem cell therapy and acute graft-versus-host disease: a review. Human Cell. 27:137-150.
  9. Burdon TJ, et al. (2011). Bone Marrow Stem Cell Derived Paracrine Factors for Regenerative Medicine: Current Perspectives and Therapeutic Potential. Bone Marrow Res. 2011:207326.
  10. Murphy MB, Moncivais K, Caplan A. (2013). Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med. 45:e54.
  11. Dominici M, et al. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 8:315-317.
  12. Riordan N, et at. (2007). Cord blood in regenerative medicine: do we need immune suppression? J Trans Med 2007, 5:8.
  13. Ribatti D, et al. (2007). The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies. Cytokine & Growth Factor Re views. 18 (3-4): 327–34.
  14. Lee TJ, et al. (Jan 2013). Enhancement of osteogenic and chondrogenic differentiation of human embryonic stem cells by mesodermal lineage induction with BMP-4 and FGF2 treatment. Biochemical and Biophysical Research Communications. 430 (2): 793–7.
  15. Perrier S, Darakhshan F, Hajduch E (November 2006). IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?. FEBS Lett. 580 (27): 6289–94.
  16. Palmer, Biff F., Clegg, Deborah J. (2014). Oxygen sensing and metabolic homeostasis. Molecular and Cellular Endocrinology. 397: 51–57.
  17. Gerber HP, et al. (1999). VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med. 5(6):623-8.
  18. Lennartsson J, Rönnstrand L. (2012). Stem Cell Factor Receptor/c-Kit: From Basic Science to Clinical Implications. Physiol Rev. 92(4):1619-49.